{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:31:24Z","timestamp":1778920284149,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1124\/dmd.116.072397","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T02:23:28Z","timestamp":1476411808000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin"],"prefix":"10.1016","volume":"45","author":[{"given":"Marta","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Matheny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangfu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harma","family":"Ellens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.116.072397_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1124\/dmd.116.072397_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.clpt.6100104","article-title":"Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice","volume":"81","author":"Bailey","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.116.072397_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejps.2014.09.007","article-title":"Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling","volume":"65","author":"Bosgra","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.116.072397_bib4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/pharmaceutics7040554","article-title":"Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells","volume":"7","author":"Br\u00e4nnstr\u00f6m","year":"2015","journal-title":"Pharmaceutics"},{"key":"10.1124\/dmd.116.072397_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/FPC.0b013e32834e9e35","article-title":"Comments on Mougey et al. (2009): Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 19: 129-138","volume":"22","author":"Chu","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.116.072397_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00228-003-0573-7","article-title":"The effect of erythromycin on the pharmacokinetics of rosuvastatin","volume":"59","author":"Cooper","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.116.072397_bib7","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1021\/mp500330y","article-title":"Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine","volume":"11","author":"Drozdzik","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.116.072397_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2012.163","article-title":"Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it\u2019s not just about OATP1B1","volume":"92","author":"Elsby","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.116.072397_bib9","unstructured":"European Medicines Agency (2012) Guideline on the investigation of drug interactions. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf."},{"key":"10.1124\/dmd.116.072397_bib10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/dmd.115.067447","article-title":"The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy","volume":"44","author":"Eng","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.072397_bib11","unstructured":"Food and Drug Administration (2012) Drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm292362.pdf."},{"key":"10.1124\/dmd.116.072397_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11095-008-9752-7","article-title":"Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations","volume":"26","author":"Furukawa","year":"2009","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.116.072397_bib13","doi-asserted-by":"crossref","unstructured":"Generaux GT, Bonomo FM, Johnson M, Doan KM (2011) Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica 41:639\u2013651.","DOI":"10.3109\/00498254.2011.562566"},{"key":"10.1124\/dmd.116.072397_bib14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","article-title":"Drug-drug interaction between pitavastatin and various drugs via OATP1B1","volume":"34","author":"Hirano","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.072397_bib15","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.116.072397_bib16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/dmd.105.007534","article-title":"ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein","volume":"34","author":"Huang","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.072397_bib17","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1177\/0091270011408612","article-title":"Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose","volume":"52","author":"Ieiri","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.116.072397_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FPC.0b013e32834300cc","article-title":"The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans","volume":"21","author":"Imanaga","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.116.072397_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.116.072397_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/jps.20231","article-title":"Effect of fruit juices on the oral bioavailability of fexofenadine in rats","volume":"94","author":"Kamath","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.116.072397_bib21","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.072397_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","article-title":"Human skeletal muscle drug transporters determine local exposure and toxicity of statins","volume":"106","author":"Knauer","year":"2010","journal-title":"Circ Res"},{"key":"10.1124\/dmd.116.072397_bib23","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1124\/dmd.109.028522","article-title":"Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides","volume":"37","author":"Lan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.072397_bib24","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/dmd.115.064170","article-title":"Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2- Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug Penetration","volume":"43","author":"Liu","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.072397_bib25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1124\/jpet.114.219287","article-title":"Effects of \u03b2-blockers and tricyclic antidepressants on the activity of human organic anion transporting polypeptide 1A2 (OATP1A2)","volume":"352","author":"Lu","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.116.072397_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/HCO.0000000000000282","article-title":"Statin myopathy: over-rated and under-treated?","volume":"31","author":"Maghsoodi","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"10.1124\/dmd.116.072397_bib27","first-page":"1116","article-title":"No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor","volume":"42","author":"Martin","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.116.072397_bib28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bcp.2009.08.029","article-title":"Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil","volume":"79","author":"Ming","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.116.072397_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FPC.0b013e32831bd98c","article-title":"Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response","volume":"19","author":"Mougey","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.116.072397_bib30","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/0091270010374472","article-title":"Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast","volume":"51","author":"Mougey","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.116.072397_bib31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/jpet.103.060194","article-title":"Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human","volume":"308","author":"Nozawa","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.116.072397_bib32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1124\/jpet.113.208314","article-title":"Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver","volume":"347","author":"Pfeifer","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.116.072397_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1124\/jpet.113.207472","article-title":"Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes","volume":"347","author":"Pfeifer","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.116.072397_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12377","article-title":"Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin","volume":"78","author":"Prueksaritanont","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.116.072397_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bcp.2016.02.011","article-title":"The C421A (Q141K) polymorphism enhances the 3\u2032-untranslated region (3\u2032-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2","volume":"104","author":"Ripperger","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.116.072397_bib36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.112.200691","article-title":"Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation","volume":"344","author":"Shen","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.116.072397_bib37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.109.159756","article-title":"Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat","volume":"332","author":"Shirasaka","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.116.072397_bib38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11095-008-9771-4","article-title":"Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp)","volume":"26","author":"Shirasaka","year":"2009","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.116.072397_bib39","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/jps.22586","article-title":"Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and\/or P-glycoprotein","volume":"100","author":"Shirasaka","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.116.072397_bib40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2133\/dmpk.DMPK-10-RG-073","article-title":"Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein\/multidrug resistance 1","volume":"26","author":"Shirasaka","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.116.072397_bib41","first-page":"1","article-title":"Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants","volume":"5","author":"Talameh","year":"2014","journal-title":"J Pharmacogenomics Pharmacoproteomics"},{"key":"10.1124\/dmd.116.072397_bib42","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.addr.2011.07.007","article-title":"Oral drug delivery utilizing intestinal OATP transporters","volume":"64","author":"Tamai","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.116.072397_bib43","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1365-2125.2010.03898.x","article-title":"Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren","volume":"71","author":"Tapaninen","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.116.072397_bib44","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1124\/dmd.107.019273","article-title":"Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers","volume":"36","author":"Tian","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.072397_bib45","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1124\/dmd.112.049023","article-title":"Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1","volume":"41","author":"van de Steeg","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.116.072397_bib46","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/mp200103h","article-title":"pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1","volume":"8","author":"Varma","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.116.072397_bib47","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1124\/jpet.107.125831","article-title":"The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin","volume":"322","author":"Windass","year":"2007","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624052978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624052978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.116.072397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:20:19Z","timestamp":1739902819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624052978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0090955624052978"],"URL":"https:\/\/doi.org\/10.1124\/dmd.116.072397","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.116.072397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}